In latest AI tie-up, Sanofi partners with Insilico for six new targets
Sanofi has inked a deal with AI drug company Insilico, marking the Big Pharma’s third major AI drug deal this year.
The deal is for up to six undisclosed targets, the duo announced this morning. Sanofi will dish out $21.5 million upfront, and downstream milestones could add up to $1.2 billion, according to Sanofi.
“This collaboration will leverage our complementary capabilities, as well as the co-location of our scientific teams, to boost the drug discovery efforts of the Sanofi Institute for Biomedical Research (SIBR), Sanofi’s R&D center in China,” Sanofi’s head of China research Changchun Xiao said. Insilico is based out of Hong Kong and New York.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.